Background/Aims: Atomoxetine (ATX), a selective norepinephrine reuptake inhibitor, is the first approved non-stimulant drug for treatment of attention deficit/hyperactivity disorder (AD/HD). The present study examined the effects of long-term treatment with ATX on prefrontal hemodynamic activity in AD/HD children during a continuous performance task (CPT) using near-infrared spectroscopy (NIRS). Methods: Prefrontal hemodynamic activity was measured in 12 children with AD/HD during experimental sessions conducted before and 6 months or more after starting ATX treatment. The average maintenance dose of ATX was 1.6 mg/kg/day. Fourteen age-matched typically developing children participated as a control group. Results: In the control group, the CPT induced a significant increase in oxygenated hemoglobin (oxy-Hb) concentration in the bilateral dorsolateral prefrontal cortex (DLPFC). In the AD/HD group in the pre-ATX condition, the CPT did not induce a significant increase in oxy-Hb concentration in any of the NIRS channels, but induced a significant decrease in oxy-Hb concentration in the left ventrolateral prefrontal cortex (VLPFC). In the AD/HD group in the post-ATX condition, significant activation was observed in the right DLPFC and the decrease in oxy-Hb concentration in the left VLPFC disappeared. Conclusions: These results suggest that long-term treatment with ATX improved prefrontal hemodynamic activity in AD/HD children, and NIRS may be useful for assessment of the prefrontal hemodynamic response to ATX treatment.
Introduction
Attention deficit/hyperactivity disorder (AD/HD) is a developmental disorder that is characterized by ageinappropriate levels of inattention, hyperactivity, and impulsivity and affects 3-7% of school-aged children [1] . Although the etiology has not been fully identified, it is empirically known that these main symptoms are improved by treatment with psychostimulants such as methylphenidate (MPH) and amphetamine.
MPH, the most common treatment for AD/HD, is an indirect catecholamine agonist that blocks both dopamine and norepinephrine transporters and thereby increases extracellular levels of these neurotransmitters at synaptic sites [2] . Recent animal studies using in vivo microdialysis demonstrated that oral administration of a clinically relevant dose of MPH produced a 
